TWI890738B - 用於預防或治療病毒性陰道周邊部疾病的藥物組成物 - Google Patents

用於預防或治療病毒性陰道周邊部疾病的藥物組成物

Info

Publication number
TWI890738B
TWI890738B TW110105759A TW110105759A TWI890738B TW I890738 B TWI890738 B TW I890738B TW 110105759 A TW110105759 A TW 110105759A TW 110105759 A TW110105759 A TW 110105759A TW I890738 B TWI890738 B TW I890738B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutical composition
vaginal
present
aforementioned
Prior art date
Application number
TW110105759A
Other languages
English (en)
Chinese (zh)
Other versions
TW202216142A (zh
Inventor
小野木博
山口哲夫
佐藤克彥
Original Assignee
日商基諾製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商基諾製藥股份有限公司 filed Critical 日商基諾製藥股份有限公司
Publication of TW202216142A publication Critical patent/TW202216142A/zh
Application granted granted Critical
Publication of TWI890738B publication Critical patent/TWI890738B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110105759A 2020-10-28 2021-02-19 用於預防或治療病毒性陰道周邊部疾病的藥物組成物 TWI890738B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-180339 2020-10-28
JP2020180339 2020-10-28

Publications (2)

Publication Number Publication Date
TW202216142A TW202216142A (zh) 2022-05-01
TWI890738B true TWI890738B (zh) 2025-07-21

Family

ID=81382191

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110105759A TWI890738B (zh) 2020-10-28 2021-02-19 用於預防或治療病毒性陰道周邊部疾病的藥物組成物

Country Status (11)

Country Link
US (1) US20230398107A1 (https=)
EP (1) EP4238565B1 (https=)
JP (1) JP7606239B2 (https=)
KR (1) KR20230098175A (https=)
CN (1) CN115734782A (https=)
CA (1) CA3199945A1 (https=)
ES (1) ES3045576T3 (https=)
PL (1) PL4238565T3 (https=)
TW (1) TWI890738B (https=)
WO (1) WO2022091442A1 (https=)
ZA (1) ZA202304812B (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009020198A1 (ja) * 2007-08-03 2009-02-12 Kinopharma, Inc. 抗ｄｎａウイルス作用を有するアニリン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63275519A (ja) * 1987-05-06 1988-11-14 Taisho Pharmaceut Co Ltd 難溶性薬物含有顆粒の製造方法
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
JP2007517062A (ja) 2003-12-29 2007-06-28 アルザ・コーポレーシヨン 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング
JP2010189337A (ja) * 2009-02-19 2010-09-02 Asahi Breweries Ltd 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法
JP6138635B2 (ja) * 2013-08-30 2017-05-31 旭化成株式会社 セルロース系核粒子及びその製造方法
WO2020218518A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法
WO2020218517A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009020198A1 (ja) * 2007-08-03 2009-02-12 Kinopharma, Inc. 抗ｄｎａウイルス作用を有するアニリン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Ajiro et al. CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia Clinical Cancer Research 24(18) 2018 4518-4528 *

Also Published As

Publication number Publication date
WO2022091442A1 (ja) 2022-05-05
JP7606239B2 (ja) 2024-12-25
KR20230098175A (ko) 2023-07-03
EP4238565C0 (en) 2025-09-24
PL4238565T3 (pl) 2025-12-22
ES3045576T3 (en) 2025-11-28
EP4238565A4 (en) 2024-10-09
CA3199945A1 (en) 2022-05-05
EP4238565A1 (en) 2023-09-06
JPWO2022091442A1 (https=) 2022-05-05
EP4238565B1 (en) 2025-09-24
TW202216142A (zh) 2022-05-01
US20230398107A1 (en) 2023-12-14
ZA202304812B (en) 2024-08-28
CN115734782A (zh) 2023-03-03

Similar Documents

Publication Publication Date Title
CN101422585B (zh) 含有莪术油的药物组合物的制药用途
CA2928166C (en) Use of a combination of lopinavir and ritonavir in the treatment of human papilloma virus (hpv) and cancers arising therefrom
TWI415633B (zh) Solid preparations containing enteric solid dispersions
US20240148729A1 (en) Lopinavir and ritonavir for the treatment of cervix disorders
EA024609B1 (ru) Лечение боли, обусловленной дислокацией базального слоя эндометрия
EP3424512A1 (en) Uses of alginic acid sulfate in preparation of drugs and health care products for preventing and treating diseases caused by human papilloma viruses
CN102307575B (zh) 含醋氯芬酸的控释口服药制剂及其制造方法
TWI890738B (zh) 用於預防或治療病毒性陰道周邊部疾病的藥物組成物
WO2019224777A1 (en) Pharmaceutical compositions
US20230285287A1 (en) Pharmaceutical compositions
CN103599093B (zh) 一种抗hpv药物制剂及用途
HK40083240A (en) Pharmaceutical composition for preventing or treating viral perivaginal disease
TWI799923B (zh) 硫代咪唑烷酮藥物在治療covid-19疾病中的用途
WO2025147598A1 (en) Device system and use for hpv infection and cervical intraepithelial neoplasia
WO2025160227A1 (en) Advantageous compounds for treatment of hpv infection and hpv-induced neoplasia
WO2025147262A1 (en) Device system and use for hpv infection and cervical intraepithelial neoplasia
EP4046646A1 (en) Pharmaceutical composition for the treatment of hpv infections
CN115666565A (zh) 用于治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的雄激素受体抑制剂
WO2022142154A1 (zh) 硫代咪唑烷酮药物在治疗covid-19疾病中的用途
HK1243360B (zh) 用於治疗子宫颈非典型性增生或子宫颈癌的包含亚硒酸盐或含亚硒酸盐化合物的药物制剂